24th Jun 2008 10:23
|
For Immediate Release |
24 June 2008 |
MINSTER PHARMACEUTICALS PLC
("Minster" or "the Company")
Result of Annual General Meeting
Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, announces that following its Annual General Meeting which was held earlier today, all resolutions put to the shareholders were passed.
For further information:
|
Minster Pharmaceuticals plc |
Tel: +44 (0) 1799 506623 |
|
Paul Sharpe, Chief Executive Officer |
|
|
Robert Aubrey, Chief Financial Officer |
|
|
Buchanan Communications |
Tel: +44 (0) 20 7466 5000 |
|
Mark Court |
|
|
Rebecca Skye Dietrich |
|
|
Catherine Breen |
|
|
Nomura Code Securities Limited |
Tel: +44 (0) 20 7776 1200 |
|
Richard Potts |
|
|
Gerard Harper |
Notes for editors:
About Minster Pharmaceuticals plc
Minster Pharmaceuticals is a drug development company focussed on neurological and psychiatric disorders. Its principal pipeline assets are tonabersat, under development in the preventive treatment of migraine, and sabcomeline in schizophrenia. Worldwide rights to both compounds were acquired from GlaxoSmithKline and the compounds benefit from comprehensive safety tolerance data as a result of investment by GSK.
Tonabersat is the leading compound in an exciting new class of selective drugs designated as neuronal gap junction blockers and offers the potential to prevent the onset of migraine as a preferred alternative to acute treatment. Sabcomeline, a muscarinic partial agonist, has potential in the treatment of chronic schizophrenia.
Minster's near-term focus is on the development and commercialisation of its current pipeline. Its medium term strategy is to leverage the anticipated cashflows from the current pipeline by in-licensing further compounds with the ultimate objective of creating a substantial and highly efficient drug development enterprise focussed on the central nervous system.
Minster joined the AIM market in February 2005 and trades under the symbol MPM. For further information please visit www.minsterpharma.com .
Related Shares:
MPM.L